Full-Time

Clinical Trial Assistant II

Clinical Operations

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$75k - $90kAnnually

Junior, Mid

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in biological sciences or related health related field required.
  • 1 - 3 years of relevant experience in the pharmaceutical or biotech industry, preferably in clinical operations or clinical research-related experience.
  • Excellent written and verbal communication skills.
  • Demonstrate proficiency in Microsoft Word, Excel and PowerPoint and other software platforms.
  • Demonstrated ability to multi-task, prioritize options.
  • Travel up to (~25%).
Responsibilities
  • Assisting in the development, review, distributing, and archiving of study specific documents and reports (plans, training materials, study guides, manuals, etc.)
  • Assisting with updating and maintaining clinical systems and any reporting tools.
  • Set up and maintenance of the trial master files (TMF) if applicable, or work with CRO to audit and resolve discrepancies.
  • Create, maintain, and track information for key study related activities.
  • Assisting in the preparation of meeting materials, scheduling meetings, and developing agendas, taking meeting minutes for internal clinical operation team meetings.
  • Gathering investigator and site information, to support study start-up, maintenance and close out activities.
  • Working with cross functional study teams, and vendors to assist in the coordination of clinical trial activities.
  • Support other clinical operations activities as appropriate.
Desired Qualifications
  • Preferably in clinical operations or clinical research-related experience.
  • Experience in oncology clinical trials.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity